These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

769 related articles for article (PubMed ID: 9210715)

  • 1. Comparison of serum prostate specific membrane antigen, prostate specific antigen, and free prostate specific antigen levels in radical prostatectomy patients.
    Douglas TH; Morgan TO; McLeod DG; Moul JW; Murphy GP; Barren R; Sesterhenn IA; Mostofi FK
    Cancer; 1997 Jul; 80(1):107-14. PubMed ID: 9210715
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation and comparison of two new prostate carcinoma markers. Free-prostate specific antigen and prostate specific membrane antigen.
    Murphy GP; Barren RJ; Erickson SJ; Bowes VA; Wolfert RL; Bartsch G; Klocker H; Pointner J; Reissigl A; McLeod DG; Douglas T; Morgan T; Kenny GM; Ragde H; Boynton AL; Holmes EH
    Cancer; 1996 Aug; 78(4):809-18. PubMed ID: 8756376
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Human glandular kallikrein 2 levels in serum for discrimination of pathologically organ-confined from locally-advanced prostate cancer in total PSA-levels below 10 ng/ml.
    Haese A; Graefen M; Steuber T; Becker C; Pettersson K; Piironen T; Noldus J; Huland H; Lilja H
    Prostate; 2001 Oct; 49(2):101-9. PubMed ID: 11582588
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preoperative prostate-specific antigen isoform p2PSA and its derivatives, %p2PSA and prostate health index, predict pathologic outcomes in patients undergoing radical prostatectomy for prostate cancer.
    Guazzoni G; Lazzeri M; Nava L; Lughezzani G; Larcher A; Scattoni V; Gadda GM; Bini V; Cestari A; Buffi NM; Freschi M; Rigatti P; Montorsi F
    Eur Urol; 2012 Mar; 61(3):455-66. PubMed ID: 22078333
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The free/total prostate-specific antigen ratio (%fPSA) is the best predictor of tumor involvement in the radical prostatectomy specimen among men with an elevated PSA.
    Grossklaus DJ; Smith JA; Shappell SB; Coffey CS; Chang SS; Cookson MS
    Urol Oncol; 2002; 7(5):195-8. PubMed ID: 12644216
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of percent free PSA, PSA density, and age-specific PSA cutoffs for prostate cancer detection and staging.
    Catalona WJ; Southwick PC; Slawin KM; Partin AW; Brawer MK; Flanigan RC; Patel A; Richie JP; Walsh PC; Scardino PT; Lange PH; Gasior GH; Loveland KG; Bray KR
    Urology; 2000 Aug; 56(2):255-60. PubMed ID: 10925089
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of various combinations of free, complexed and total prostate-specific antigen levels as predictors of the pathologic stage of prostate cancer.
    Okegawa T; Noda H; Ohta M; Kato M; Nutahara K; Higashihara E
    Int J Urol; 2001 Aug; 8(8):438-43. PubMed ID: 11555010
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of PSA, free PSA, PSMA, and total and bone alkaline phosphatase levels compared to bone scans in the management of patients with metastatic prostate cancer.
    Murphy GP; Troychak MJ; Cobb OE; Bowes VA; Kenny RJ; Barren RJ; Kenny GM; Ragde H; Holmes EH; Wolfert RL
    Prostate; 1997 Oct; 33(2):141-6. PubMed ID: 9316655
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk assessment for biochemical recurrence prior to radical prostatectomy: significant enhancement contributed by human glandular kallikrein 2 (hK2) and free prostate specific antigen (PSA) in men with moderate PSA-elevation in serum.
    Steuber T; Vickers AJ; Haese A; Becker C; Pettersson K; Chun FK; Kattan MW; Eastham JA; Scardino PT; Huland H; Lilja H
    Int J Cancer; 2006 Mar; 118(5):1234-40. PubMed ID: 16152616
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preoperative prostate-specific antigen isoform p2PSA ≤ 22.5 pg/ml predicts advanced prostate cancer in patients undergoing radical prostatectomy.
    Eminaga O; Bögemann M; Breil B; Titze U; Wötzel F; Eltze E; Bettendorf O; Semjonow A
    Urol Oncol; 2014 Nov; 32(8):1317-26. PubMed ID: 24893699
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Volume indexes of total, free, and complexed prostate-specific antigen enhance prediction of extraprostatic disease extension in men with nonpalpable prostate cancer.
    Naya Y; Fritsche HA; Cheli CD; Stamey TA; Bartsch G; Brawer MK; Childs S; Taneja SS; Lepor H; Partin AW; Sokoll LJ; Chan DW; Babaian RJ
    Urology; 2003 Dec; 62(6):1058-62. PubMed ID: 14665355
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum half-life time determination of free and total prostate-specific antigen following radical prostatectomy--a critical assessment.
    Brändle E; Hautmann O; Bachem M; Kleinschmidt K; Gottfried HW; Grünert A; Hautmann RE
    Urology; 1999 Apr; 53(4):722-30. PubMed ID: 10197847
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of the complexed-to-total prostate-specific antigen ratio in predicting the final pathological stage of clinically localized prostate cancer.
    Martínez M; Navarro S; Medina P; Villavicencio H; Rioja L; Solsona E; Estellés A; Aznar J; Jiménez-Cruz JF; España F
    Eur Urol; 2003 Jun; 43(6):609-14. PubMed ID: 12767360
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Human glandular kallikrein as a tool to improve discrimination of poorly differentiated and non-organ-confined prostate cancer compared with prostate-specific antigen.
    Recker F; Kwiatkowski MK; Piironen T; Pettersson K; Huber A; Lümmen G; Tscholl R
    Urology; 2000 Apr; 55(4):481-5. PubMed ID: 10736487
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of predictive accuracy for pathologically organ confined clinical stage T1c prostate cancer using human glandular kallikrein 2 and prostate specific antigen combined with clinical stage and Gleason grade.
    Haese A; Vaisanen V; Lilja H; Kattan MW; Rittenhouse HG; Pettersson K; Chan DW; Huland H; Sokoll LJ; Partin AW
    J Urol; 2005 Mar; 173(3):752-6. PubMed ID: 15711262
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pre-operative percent free PSA predicts clinical outcomes in patients treated with radical prostatectomy with total PSA levels below 10 ng/ml.
    Shariat SF; Abdel-Aziz KF; Roehrborn CG; Lotan Y
    Eur Urol; 2006 Feb; 49(2):293-302. PubMed ID: 16387412
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular staging by RT-pCR analysis for PSA and PSMA in peripheral blood and bone marrow samples is an independent predictor of time to biochemical failure following radical prostatectomy for clinically localized prostate cancer.
    Mitsiades CS; Lembessis P; Sourla A; Milathianakis C; Tsintavis A; Koutsilieris M
    Clin Exp Metastasis; 2004; 21(6):495-505. PubMed ID: 15679047
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Electrophoretic subforms of free prostate-specific antigen in serum as promising diagnostic tool in prostate cancer diagnostics.
    Jung K; Hoesel W; Reiche J; Deger S; Kramer J; Loening SA; Lein M; Stephan C
    Urology; 2007 Feb; 69(2):320-5. PubMed ID: 17320672
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The free-to-total serum prostatic specific antigen ratio as a predictor of the pathological features of prostate cancer.
    Morote J; Encabo G; Lopez MA; De Torres IM
    BJU Int; 1999 Jun; 83(9):1003-6. PubMed ID: 10368244
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of positive surgical margins on prostate-specific antigen failure after radical prostatectomy in adjuvant treatment-naïve patients.
    Ploussard G; Agamy MA; Alenda O; Allory Y; Mouracade P; Vordos D; Hoznek A; Abbou CC; de la Taille A; Salomon L
    BJU Int; 2011 Jun; 107(11):1748-54. PubMed ID: 20883488
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 39.